Last reviewed · How we verify
NCT06133647
Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System
trial testing managing Male Breast Cancer Patients at Methodist Health System in Ductal Carcinoma in Situ in 8 participants. Completed in 1 May 2025.
1 May 2025
Quick facts
| Lead sponsor | Methodist Health System |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 4 May 2023 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- managing Male Breast Cancer Patients at Methodist Health System
Conditions studied
- Ductal Carcinoma in Situ — all drugs for Ductal Carcinoma in Situ →
- Invasive Lobular Breast Carcinoma — all drugs for Invasive Lobular Breast Carcinoma →
Sponsor
Methodist Health System — full company profile →
Who can join
Adults 18 to 85, any sex, with Ductal Carcinoma in Situ or Invasive Lobular Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinicopathologic Features and Prognoses of Male Patients With Breast Cancer.
Huang M, Xiao J, Yan C, Ling R, et al · · 2024 · PMID 39365001 · DOI 10.1177/15579883241284981
Verify or expand the search:
- PubMed search for NCT06133647
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ductal Carcinoma in Situ
Currently open trials in the same condition.
- NCT07095114 — A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. · NA · recruiting
- NCT06218303 — Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ · Phase 1 · recruiting
- NCT06677944 — Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer · Phase 2 · recruiting
- NCT05218044 — Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ · NA · recruiting
- NCT04666961 — Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ · Phase 2 · recruiting
Other Methodist Health System trials
Trials by the same sponsor.
- NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
- NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
- NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
- NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
- NCT07492758 — Management of Extremity Injuries Registry · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06133647 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
- Last refreshed: 27 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06133647.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing